Singapore – Roche unit Genentech announces new four-year data from an open-label extension study of OCREVUS (ocrelizumab) in patients with relapsing multiple sclerosis (MS). The results were presented at the American Academy of Neurology Annual Meeting in Los Angeles.

Patients experienced sustained reductions in disease activity, delayed cognitive decline and improved cognitive function. Participants also showed reductions in biomarkers for nerve damage and inflammation.

OCREVUS, approved in the U.S. in March 2017, is commercially available in over 55 countries.